Video Library

What is the role for the neuroprotective agent memantine in patients receiving whole brain radiation therapy for brain metastases? Dr. Vivek Mehta reviews current practices to minimize risk of cognitive problems. Please feel free to offer comments and raise questions in our Discussion Forums

Radiation Oncologist Dr. Vivek Mehta reviews the concept of using whole brain radiation for multiple brain metastases, including how it is delivered and risks and benefits of this strategy. Please feel free to offer comments and raise questions in our Discussion Forums. Transcript I see a number of

Radiation therapy can be very helpful in treating painful bone metastases or those at risk for causing a fracture due to compromise of bone strength. Dr. Vivek Mehta reviews the basics of this approach. Please feel free to offer comments and raise questions in our Discussion Forums. Transcript

Dr. Nasser Hanna, Indiana University Health, addresses the issue of prophylactic cranial irradiation (PCI) in locally advanced NSCLC.

Transcript One of the important points about patients with advanced lung cancer is that 30-40% of patients will develop bone metastases. I think it’s important to recognize this is not bone cancer, this is lung cancer that’s moved to the bone, and in 30-40% of patients at some point who have

Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.

Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).

Dr. Alice Shaw joined GRACE to discuss controlling brain metastases in patients with molecular driven advanced non-small cell lung cancer.

Dr. Alice Shaw joined GRACE to discuss patterns of resistance in ALK positive non small cell lung cancer.

Dr. Alice Shaw joined GRACE to discuss the changing landscape of first-line treatment of ALK-positive advanced non-small cell lung cancer.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses evolving options in first line treatment of ALK-Positive non-small cell lung cancer (NSCLC).

For this new addition to the GRACE Lung Cancer Video Library, Dr. Charu Aggarwal joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Aggarwal discusses updated information on the utility of liquid biopsies. To join the conversation, visit https://cancergrace.org

GRACE is excited to bring you a new series on current updates in Melanoma Treatment Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chiefof Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University